Fingolimod hydrochloride CAS:162359-56-0

CAS NO: 162359-56-0
Fingolimod hydrochloride CAS:162359-56-0
Description Review
Description

Fingolimod Hydrochloride, also known as FTY720-HCl or Gilenya, is a medication used to treat multiple sclerosis (MS). It was developed by Novartis and approved by the US Food and Drug Administration (FDA) in 2010 for the treatment of relapsing-remitting MS.

Chemical name:

The chemical name of Fingolimod Hydrochloride is (S)-2-amino-2-(2-[4-octylphenyl]ethyl)propane-1,3-diol hydrochloride.

Molecular formula:

The molecular formula of Fingolimod Hydrochloride is C19H34ClNO2.

Formula weight:

The formula weight of Fingolimod Hydrochloride is 343.92 g/mol.

CAS No:

The CAS number of Fingolimod Hydrochloride is 162359-56-0.

Top ten keywords from Google and synonyms:

  1. Gilenya side effects
  2. Fingolimod mechanism of action
  3. Fingolimod clinical trials
  4. Fingolimod dosage
  5. FTY720-HCl pharmacokinetics
  6. Multiple sclerosis treatment
  7. Neurological disorders
  8. Immune-modulating therapy
  9. FTY720-HCl safety
  10. Gilenya benefits

Synonyms: FTY720-HCl, Gilenya, (S)-2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride

Health benefits of Fingolimod Hydrochloride:

Fingolimod Hydrochloride has been primarily used for the treatment of multiple sclerosis (MS). Specifically, it is used to reduce the frequency of relapses and slow down the progression of disability associated with MS. Moreover, it may help to decrease inflammation and prevent damage to neurons in the brain and spinal cord.

Potential Effects:

Fingolimod Hydrochloride works by modulating the activity of immune cells that contribute to the development and progression of MS. By binding to specific receptors on immune cells, Fingolimod Hydrochloride prevents them from leaving lymph nodes and entering the bloodstream. As a result, these immune cells are unable to reach the brain and spinal cord, where they would otherwise attack and damage nerve cells. This immune-modulating effect of Fingolimod Hydrochloride can help to reduce the frequency and severity of MS relapses and slow down the progression of disability.

Product Mechanism:

Fingolimod Hydrochloride is a sphingosine-1-phosphate receptor modulator that binds to specific receptors on immune cells called sphingosine-1-phosphate (S1P) receptors. By binding to these receptors, Fingolimod Hydrochloride blocks the ability of immune cells to exit from lymph nodes and enter the bloodstream. As a result, fewer immune cells are able to reach the central nervous system, which helps to prevent inflammation and neurodegeneration in MS patients.

Safety:

Like any medication, Fingolimod Hydrochloride may have some potential side effects. However, most reported side effects of Fingolimod Hydrochloride are mild to moderate in severity and manageable. Common side effects include headache, fatigue, diarrhea, back pain, and cough. In rare cases, severe adverse reactions such as liver damage, heart problems, and infections may occur. Therefore, it is important to discuss the risks and benefits of Fingolimod Hydrochloride with your doctor before taking it.

Dosing Information:

The recommended dosage of Fingolimod Hydrochloride for the treatment of MS is 0.5 mg once daily. The medication should be taken orally with or without food. Patients should be monitored for at least six hours after the first dose of Fingolimod Hydrochloride to ensure that their heart rate and blood pressure remain stable. If a dose is missed, patients should take the next scheduled dose at the regular time. Patients should not take a double dose of Fingolimod Hydrochloride to make up for the missed dose.

Conclusion:

In conclusion, Fingolimod Hydrochloride is an effective treatment for multiple sclerosis that works by modulating the activity of immune cells. It helps to reduce the frequency of relapses and slow down the progression of disability associated with MS. Although Fingolimod Hydrochloride has shown potential benefits in clinical trials, more studies are needed to establish its long-term safety and efficacy. Therefore, patients should always consult with their healthcare provider before starting any new medication

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us